)
Killian Hanlon
CEO & Chief Scientist,
Lir Therapeutics
Killian Hanlon is CEO of Lir Therapeutics, and has spent 15 years building gene therapies and viral capsids across a wide variety of neurological and sensory disorders. His research focuses on how gene therapy can be improved at every stage: how the building blocks of better therapies are designed, and how to make genetic medicine a reality for any disease.
Sessions
-
Panel Discussion: Designing the Next Generation of Rare Disease Therapies: From Advanced Genomics to AI-Enabled Therapeutic Innovation27-Jan-2027Advanced Therapies Stage